The Law of Interia

With the broad market indices insisting on not moving much, just yet, it remains tough to force the issue in terms of attacking even the most attractive individual chart. 

Two possible exceptions, however, reside in the biotechnology, names we have highlighted but here and with Members. 

FATE is having a very strong session on a huge uptick of buy volume, and Repligen, pictured below on its daily chart, is likewise threatening a fresh breakout of its own. 

Whether or not to take the plunge and buy FATE RGEN depends on your risk tolerance, as well as to how heavily long you are already, if at all. While the S&P 500 Index remains above 2800, the IWM small caps are proving inept once again, and chips are not faring much better in the SMH. 

Another day of mixed signals, with select growth stocks shining but quite a few headwinds yet to be resolved, beyond the trade war headlines.